- Price
- $51.83
- Day
- +0.27%
- Mkt Cap
- $77.04B
- 52W Range
- $42.20 – $109.50
- Volume
- 16.27M
- Beta
- 0.57
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
Boston Scientific has corrected sharply due to EP and WATCHMAN slowdowns, but 74% of its portfolio continues healthy growth. Weakness in BSX's EP business appears addressable with new product launches like FARAWAVE Ultra and ICE, expected to drive recovery from 2H 2027 onward. Valuation is compelling: BSX trades at 15.27x forward earnings, a significant discount to peers and historical averages, despite resilient core businesses.
B. Riley Wealth Advisors Inc. Trims Holdings in Boston Scientific Corporation $BSX
B. Riley Wealth Advisors Inc. reduced its stake in Boston Scientific Corporation (NYSE: BSX) by 56.1% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 8,467 shares of the medical equipment provider's stock after selling 10,822 shares during the quarter. B. Riley Wealth
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Boston Scientific Corporation $BSX Shares Sold by E. Ohman J or Asset Management AB
E. Ohman J or Asset Management AB cut its holdings in Boston Scientific Corporation (NYSE: BSX) by 91.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,275 shares of the medical equipment provider's stock after selling 541,890 shares during the
Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone
Boston Scientific has been heavily sold off, now trading at attractive valuations versus peers after multiple guidance cuts. Despite U.S. growth headwinds for WATCHMAN and electrophysiology, BSX delivered strong Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth. International markets are driving robust growth for BSX, with electrophysiology up 23.1% and WATCHMAN up 17.7% outside the U.S.